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Abstract
Background: Numerous patient and healthcare system-related delays contribute to the overall delay experienced by
patients from onset of TB symptoms to diagnosis and treatment. Such delays are critical as infected individuals remain
untreated in the community, providing more opportunities for transmission of the disease and adversely affecting the
epidemic.
Methodology/Principal Findings: We present an analysis of the factors that contribute to the overall delay in TB diagnosis
and treatment, in a resource-poor setting. Impact on the distribution of diagnostic delay times was assessed for various
factors, the sensitivity of the diagnostic method being found to be the most significant. A linear relationship was found
between the sensitivity of the test and the predicted mean delay time, with an increase in test sensitivity resulting in a
reduced mean delay time and a reduction in the drop-out rate.
Conclusions/Significance: The results show that in a developing country a number of delay factors, particularly the low
sensitivity of the initial sputum smear microscopy test, potentially increase total diagnostic delay times experienced by TB
patients significantly. The results reinforce the urgent need for novel diagnostic methods, both for smear positive and
negative TB, that are highly sensitive, accessible and point of care, in order to reduce mean delay times.
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Introduction
Tuberculosis (TB) is currently the world’s leading cause of death
from a single infectious condition. Despite widespread introduc-
tion of the Directly Observed Therapy Short-course (DOTS)
program, heralded as ‘‘one of the major public health success
stories of the past decade’’, incidence of the disease continues to
rise in many sub-Saharan African countries, exacerbated by high
levels of HIV. In 2005, the estimated TB case load in South Africa
alone was over 470, 000.[1]
Case detection, specifically excessive delays in correct TB
diagnosis and treatment remains a weakness of the control strategy
and has been the focus of much research [2–4]. Such delays result
in greater opportunity for patients to infect susceptible individuals
and may contribute significantly to the high incidence levels
evident in many developing countries [1,5–7]. In order to control
the TB epidemic it is therefore vitally important to identify and
reduce these delays. This implies that it is necessary to fully
understand the causes of these delays and to estimate their
magnitudes so as to enable the planning of interventions that yield
the maximum benefit.
Before correct diagnosis is achieved and treatment started there
are a large number of delay factors that contribute to an overall
delay time. There are inherent delays in the current diagnostic
process such as time taken to collect, transport and examine
sputum samples for sputum smear microscopy (SSM). However a
TB case may also experience any one of a large number of
sequences of events or circumstances that contribute to the total
delay and are subject to a certain amount of random variation.
Such events or circumstances are largely associated with the care
seeking behaviour of patients. [8]
A simulation model was developed to enable an investigation to
be carried out into the relative importance of each of the potential
delays. We use the model to calculate the total time, from onset of
symptoms until diagnosis, based on probabilities for the transition
from one event to another and their associated delays. The
simulation was repeated a number of times to generate a delay
time distribution and the sensitivity of this to each parameter, be it
a transition probability or an associated delay, could then be
determined.
Methods
A decision tree simulation model was used to analyse the delays
that occur between the onset of TB symptoms through to diagnosis
and treatment. All individuals in the model are assumed to be
positive for TB and only pulmonary TB cases are considered, since
these have the potential to infect others. We describe below, the
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various events represented in the model that can contribute to the
total delay before reaching a definite diagnosis and the start of
treatment.
A prospective patient enters the model after showing symptoms
of TB, most commonly a cough, of three weeks duration. The
individual then has the option of one of the following:
N Seek no help at all.
N Visit a health care provider.
Those in the former category are assumed to remain infectious
in the community until such a time that the patient self-cures or
dies. Although such individuals are likely to infect others and as a
result lead to a greater number of TB cases to be managed by the
healthcare system, this phenomenon is not included in this
simulation. Infected individuals that seek a healthcare provider
may either:
N Visit a health care provider who has no facility for testing TB.
N Visit a health care provider who can test for TB.
The former includes traditional healers, homeopaths or any
form of therapy/treatment which is not centred on standard
clinical tests and treatment for TB. Such a healthcare encounter is
assumed to have negligible effect on the patient’s condition.
Having sought a non-TB specific health provider the individual
may continue with such therapy, drop out and seek no further care
or proceed to seek standard TB-specific healthcare.
In the latter case the infected individual seeks formal TB care.
No distinction is made between a dedicated TB clinic and a
hospital, be it public or private, but considers only those that
practice according to the NTCP (national tuberculosis control
programme). Upon visiting the TB healthcare provider the patient
may experience any one of the following:
N S/he may be treated for the cough, but not for TB, and
discharged.
N A CXR may be taken.
N A sputum sample may be taken for diagnostic tests, and further
samples requested.
In the first event the patient may drop out or may, given that
symptoms persist, make further visits to the TB-test facility. For
simplicity, we exclude the possibility that, having been to a TB-test
facility, the patient then goes back to an alternative health care
provider.
If a CXR is carried out and is judged to be normal, a negative
diagnosis is given and the patient is discharged. If the CXR is
abnormal, together with symptoms indicating TB, a positive
diagnosis may be made and treatment begun. However the
following delays may be incurred:
N The delay in taking the CXR.
N The delay in producing the results.
N The delay in the patient collecting the results.
N The delay in the start of treatment, given a positive diagnosis.
In the event that sputum samples are requested, numerous
delays can and do arise:
i) The delay until the first sputum sample is taken. This is
generally taken on the spot but may not be possible if the patient
finds it difficult to expectorate.
ii) The delay in producing further samples. This should be
completed the following day; however this is not always
achieved, particularly with patients living in poverty, whose
circumstances may make it difficult to access the healthcare
provider.
iii) Delay in the results being received. This includes the delay in
transporting the samples to the laboratory, then being examined
and the results recorded. Combined this usually takes 12–
48 hours. This is another opportunity for the patient to drop
out.
iv) The delay in the patient returning to collect the result, once
all of the sputum samples have been provided and the tests
completed.
v) The delay in the start of treatment, in the event that the
patient tests positive.
Despite a patient being positive for TB and receiving the correct
tests, due to the low sensitivity of SSM a negative diagnosis may
still be given. The simulation allowed us to vary the sensitivity of a
diagnostic test over a wide range in order to investigate the
theoretical limits to the effect that improved diagnostic techniques
could have on treatment delay. It is assumed in the model that TB
treatment is not started if the sputum result is negative. In the
event of an incorrect diagnosis being given the infected patient
may drop out or continue with further testing. A specific algorithm
is followed for smear negative patients suspected of having TB.
Firstly a chest X-ray is carried out which leads to one of the
following:
N The X-ray is normal, indicating a low suspicion of TB. The
patient receives a negative diagnosis but may return to the
clinic in the future.
N The X-ray is abnormal, which indicates a high suspicion of
TB. The patient may be treated presumptively based on the
CXR or go on for further testing to confirm the diagnosis.
Additional testing for patients suspected of having TB requires
further sputum samples. SSM and culture testing are initiated at
this stage; however the latter requires a considerably longer period
before results are available. Therefore, in the event of a positive
SSM result i.e. smear positive, a diagnosis is made before the
culture results are processed, otherwise the patient must wait for
up to 8 weeks for a definitive diagnosis. This stage in the
diagnostic process represents a very significant proportion of the
overall delay time and explains why smear negative patients incur
such an excessive delay between the onset of symptoms and
diagnosis and treatment and patients may drop out during this
time.
The model assumes constant transition probabilities regardless
of how many visits a patient has made. In reality this is unlikely to
be the case, as in each successive visit there will be changes in the
probabilities that patients drop out, of different tests being applied
and of which action will be taken given a particular outcome for
each test. Thus, for example, the probability that a health care
provider decides to treat TB syndromically, even in the face of
negative sputum results, will presumably increase with each test.
We also assume a constant specific probability each day that a
patient makes a visit to the TB test facility. This is equivalent to
assuming that the waiting times are exponentially distributed. It is
also implied that the mean waiting time between events is equal to
the inverse of the daily probability that the event occurs. It is
unlikely that the distribution is in fact exponential. One might
assume that the longer the patient has had the symptoms the sicker
s/he is likely to be and will thus be more likely to visit a health
provider on a particular day. In mathematical terms, the hazard is
not a constant but increases with time since onset of symptoms.
The Impact of Test Sensitivity
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Without definite data regarding the actual distribution the
constant probability approach will have to be used. Probabilities
for other events are fixed and independent of time.
It will be noted that the results of the two routinely collected
sputum specimens are not independent, but rather are highly
correlated and this consideration is incorporated in the simulation
model design. Thus if the first specimen yields a positive result, i.e.
if the specimen exceeds the threshold for the test, then it is likely
that the following specimen will also exceed this threshold and be
positive. The converse applies when the first specimen yields a
negative result. In other words, the probability of a test giving a
positive result is not only dependent on the sensitivity of the test
but depends also on the quantity of bacteria present in the sputum
and hence on the condition of the specific patient.
Results
The purpose of this investigation is to quantify the effect of various
diagnostic delays on the overall delay experienced by TB patients
before treatment is started. To this end the flowchart shown in
Figure 1. Schematic of the model.
doi:10.1371/journal.pone.0001933.g001
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figure 1 was implemented in an Excel spreadsheet using macros. The
total delay experienced by a virtual patient can be evaluated and is
dependent on the probabilities and associated delay times at each
stage. By repeating the simulation calculation many times a
distribution for total delay times can be generated. The process of
creating distributions was repeated for various parameter settings
and the mean time for each distribution was calculated.
By running the model with input parameters set to reflect the
current diagnostic protocol in South Africa (see Tables 1 and 2), a
distribution similar to that seen in figure 2 is produced. This is
based on two smear samples being used in the initial SSM test,
producing a sensitivity of 0.55. It should be emphasised that
estimates based on reports from clinics, in the Western Cape, RSA
are used for the input data and that actual documented data needs
Table 1. Standard ZN Microscopy Using Two Smears (Pre-test and smear positive parameters)
Parameters Code Name Values Reference
Total number of patients NTOT 1000 -
P(ith patient has TB) PTB 1 -
Sensitivity of Initial Diagnostic Procedure PPV 0.55 36
Maximum number of days+ve patient survives untreated SURV 1460 VAR
P(patient first visits non-clinic health provider) NCHP 0.5 VAR
Delay consequent on visit to non-TB test centre DNCHP 10 VAR
P(makes 1st visit to clinic on any given day) PHC1 0.05 VAR
P(makes 2nd visit to clinic on any given day) PHC2 0.05 VAR
P(makes 3rd visit to clinic on any given day) PHC3 0.05 VAR
P(drops out between visits 0 & 1 I NO sputum taken in visit 0) PD10 0.01 VAR
P(drops out between visits 1 & 2 I NO sputum taken in visit1) PD20 0.01 VAR
P(drops out between visits 2 & 3 I NO sputum taken in visit2) PD30 0.01 VAR
P(drops out before going to clinic for visit 1) PD11 0.01 VAR
P(drops out between visits 1 & 2 I sputum taken in visit1) PD21 0.01 VAR
P(drops out between visits 2 & 3 I sputum taken in visit2) PD31 0.01 VAR
P(clinic asks for CXR at visit 1) PCXR1 0.10 VAR
P(clinic asks for CXR at visit 2) PCXR2 0.10 VAR
P(clinic asks for CXR at visit 3) PCXR3 0.10 VAR
P(clinic treats on basis of CXR at visit 1) SENCXR1 0.50 VAR
P(clinic treats on basis of CXR at visit 2) SENCXR2 0.50 VAR
P(clinic treats on basis of CXR at visit 3) SENCXR3 0.50 VAR
Delay in treating after deciding to treat given CXR result) DELCXR 2 VAR
P(clinic asks for sputum sample at visit 1) PS1 0.95 VAR
P(clinic asks for sputum sample at visit 2) PS2 0.95 VAR
P(clinic asks for sputum sample at visit 3) PS3 0.95 VAR
P(drops out during visit 1, BEFORE giving sputum) PD12 0.01 VAR
P(drops out during visit 2, BEFORE giving sputum) PD22 0.01 VAR
P(drops out during visit 3, BEFORE giving sputum) PD32 0.01 VAR
P(drops out during visit 1, BEFORE collecting results) PD13 0.01 VAR
P(drops out during visit 2, BEFORE collecting results) PD23 0.01 VAR
P(drops out during visit 3, BEFORE collecting results) PD33 0.01 VAR
Delay in delivering sputum samples at visit 1 DEL11 1 VAR
Delay in delivering sputum samples at visit 2 DEL21 1 VAR
Delay in delivering sputum samples at visit 3 DEL31 1 VAR
Delay in lab producing results after visit 1 DEL12 2 VAR
Delay in lab producing results after visit 2 DEL22 2 VAR
Delay in lab producing results after visit 3 DEL32 2 VAR
Delay in patient collecting results after visit 1 DEL13 2 VAR
Delay in patient collecting results after visit 2 DEL23 2 VAR
Delay in patient collecting results after visit 3 DEL33 2 VAR
Delay in start of treatment after+ve diagnosis DELTR 2 22, VAR
Notes: VAR =Variable/data not available. P(Assertion 1 | Assertion 2) denotes the probability of Assertion 1 being true given the truth of Assertion 2.
doi:10.1371/journal.pone.0001933.t001
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to be gathered. However the analysis is not critically contingent on
precise data values.
Two groupings can clearly be seen within the distribution
shown in figure 2. The left hand cluster represents patients that are
diagnosed using the initial SSM test, whereas the cluster to the
right represents smear negative TB cases, largely diagnosed by the
culture test. The latter group incur significantly longer delays due
to the long period of time required to culture Mycobacterium.
The TB patients that fail to be identified by the initial SSM test
and who thus experience much longer delays form part of the
cluster to the right in figure 2. The relative size of this cluster is
dependent on the sensitivity of the test. When initial SSM test
sensitivity is increased to 0.99, as shown in figure 3, a majority of
patients receive a diagnosis based on this test and thus fall within
the left hand cluster. The distribution reveals an offset to the
overall delay time, with the minimum diagnostic delay at
approximately 10 days. This is due to the inherent delays in the
diagnostic process, such as that associated with patients producing
both samples, technicians examining sputum smears and produc-
ing the results, and the start of treatment following a positive
diagnosis. This minimum delay is associated with just one of the
many possible sequences of events that precede diagnosis. Delay
between onset of symptoms and start of treatment is exponentially
distributed due to transition probabilities that are independent of
time, such as the constant probability that a patient will make a
visit to the clinic on a given day. The interruption that can be seen
in the pattern at approximately day 15 is due to a group of
patients, positioned further to the left, who are diagnosed by the
SSM test on their first visit and a group to the right, starting on
approximately day 20, who are diagnosed also by the SSM test,
but after making a second or sometimes third visit to the clinic.
Conversely when initial SSM test sensitivity is decreased
significantly, as shown in figure 4, the proportion of TB patients
who are smear negative increases, meaning they incur additional
delays as they must wait for further test results. Due to the low
sensitivity of the additional SSM test, a majority of smear negative
patients must wait for culture results, which takes approximately
6 weeks on average to produce.
From these histograms it is clear that test sensitivity has a
significant effect on delays, specifically by influencing the
Table 2. Standard ZN Microscopy Using Two Smears (Smear negative algorithm parameters)
CXR test (smear negative patients) CXR2 0.72 36
Microscopy test (smear negative patients) PPV2 0.08 36
Culture test (smear negative patients) PPV3 1.00 36
P(smear neg. patient drops out before CXR is carried out) PDN 0.01 VAR
P(smear neg. patient drops out before collecting CXR results) PDRN 0.01 VAR
P(smear neg. patient drops out before collecting micr. results) PDRNM 0.01 VAR
P(smear neg. patient drops out before collecting culture results) PDRNC 0.05 VAR
P(decide to treat presumptively based on abnormal CXR) TRCXR 0.10 VAR
Delay in lab producing smear neg. patient’s CXR results DELN 0 VAR
Delay in lab producing smear neg. patient’s micr. results) DELM 2 VAR
Delay in lab producing smear neg. patient’s culture results DELC 42 34
Delay in smear neg. patient collecting CXR results DELPN 0 VAR
Delay in smear neg. patient collecting micr. results DELPM 1 VAR
Delay in smear neg. patient collecting culture results DELPC 5 VAR
Cost per AFB smear test (US$) (single specimen test) CAFB 4.01 25
Cost per Chest X-ray (US$) CCXR 6.60 25
Cost per LJ Culture/differential (US$) CLJC 19.04 *
Cost per Clinic Visit (US$) CCLV 3.90 25
Notes: VAR = Variable/data not available * NHLS Laboratory Costs (2004) P(Assertion 1 | Assertion 2) denotes the probability of Assertion 1 being true given the truth of
Assertion 2.
doi:10.1371/journal.pone.0001933.t002
Figure 2. Distribution of delays since onset of symptoms to
start of treatment for patients that do not drop out, using a
SSM test sensitivity of 0.55.
doi:10.1371/journal.pone.0001933.g002
Figure 3. Distribution of delays since onset of symptoms to
start of treatment for patients that do not drop out, using a
SSM test sensitivity of 0.99.
doi:10.1371/journal.pone.0001933.g003
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proportion of patients that receive a diagnosis from the initial SSM
test. However in order to quantify this effect more precisely, mean
delay was calculated from the distribution. By varying the
sensitivity of SSM (initial test for all patients) a linear relationship
with delays is produced, as shown in figure 5. Mean delay is
reduced by approximately 3 days for every 0.1 increase in test
sensitivity when this approaches 1.0 and 5 days when sensitivity is
very low. The mean delay ranges from 29.4 days when test
sensitivity is 1.0 to 70.9 days with a sensitivity of 0.1.
It is apparent that the mean length of delays experienced by
patients is greatly affected by the proportion of smear negative
patients. In order to further investigate the effect that the smear
negative algorithm has on delays, we examined other parameters.
By altering the proportion of smear negative patients that are
treated presumptively based on CXR results, the number of
patients that have to wait for culture results also changes. Due to
the aforementioned long delay associated with culture this has a
significant effect. The frequency of longer delays is reduced when
50% of smear negative cases are treated presumptively when
compared to only 10%. Figure 6 shows this effect by the resulting
smaller cluster to the right. Due to the low specificity of CXR
however, there is an increased risk of false positives associated with
this approach.
An alternative way of reducing delays associated with smear
negative patients is to reduce culture time. More rapid culture
methods are currently available, however they have other
limitations. Figure 7 shows a shift to the left of the smear negative
cluster when culture time is reduced to 28 days as is achievable
using the MGIT method. LJ culture is currently the standard
method and has a culture time of approximately 6 weeks.
Whether a TB patient is smear positive or negative, in order to
reduce the overall delay it is clear that patients must seek the
appropriate health provider as soon as possible after onset of
symptoms. Figure 8 shows the effect of doubling the probability
that a patient makes a clinic visit on a given day. When the
probability is increased, mean delay is reduced, as diagnosis and
thus treatment is started sooner. Specifically the distribution of
delays has a sharper decline, as more patients experience the
minimum delay. The four major distinguishable clusters seen in
Figure 4. Distribution of delays since onset of symptoms to
start of treatment for patients that do not drop out, using a
SSM test sensitivity of 0.01.
doi:10.1371/journal.pone.0001933.g004
Figure 5. Linear relationship between initial SSM test sensitivity
andmean number of days delayed between onset of symptoms
and start of treatment for those that did not drop out.
doi:10.1371/journal.pone.0001933.g005
Figure 6. Distribution of delays since onset of symptoms to
start of treatment for patients that do not drop out, when 0.1
(above) and 0.5 (below) smear negative patients with an
abnormal CXR are treated presumptively.
doi:10.1371/journal.pone.0001933.g006
Figure 7. Distribution of delays since onset of symptoms to
start of treatment for patients that do not drop out, when
culture takes 42 days (top) and 28 days (bottom).
doi:10.1371/journal.pone.0001933.g007
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the lower histogram when viewed from left to right represent
patients that are diagnosed mostly by the initial SSM test on their
first visit, mostly by the initial SSM test on their second visit,
mostly by the culture test on their first visit, and mostly by the
culture test on their second visit. Reference to diagnosis made on a
particular visit implies that patients make a visit to the TB test
centre and a series of tests is initiated on that visit, but completed
over a number of days.
Figure 9 shows that delay is equally affected when only the
probability of making the first visit is changed. This implies that
the second and third visits are significantly less important in terms
of overall delay.
Once a patient seeks the appropriate healthcare provider it is
then important that the correct tests are carried out. Specifically a
sputum sample should be requested if the healthcare provider
suspects TB. Figure 10 shows that for those patients that do not
drop out, the distribution of delays is significantly altered by a
decrease in probability of sputum being requested. As the
probability that sputum is requested on any of the visits decreases,
the likelihood that a patient never receives a diagnosis is increased.
Patients that do not receive a diagnosis remain untreated and
delay is therefore equal to survival time. This explains why delay
increases so rapidly when the probability of sputum being
requested is low (figure 11).
With regards to the sensitivity of smear negative tests, SSM and
CXR both have a linear effect on mean delay. However this effect is
significantly less than that of the initial SSM test due to smaller numbers
of smear negative patients. The reason for the modest gains achieved
from improvingCXR sensitivity, as shown in figure 12, is that a positive
(abnormal) result usually requires confirmation by further tests.
A linear relationship is also found between initial SSM test
sensitivity and the percentage of patients that drop out, as shown
in figure 13. At each stage in the model a patient has the option of
discontinuing diagnosis. Therefore, early diagnosis implies that fewer
visits to the clinic will be required and patients will be less likely to
drop out. A mean drop-out rate of 182 (out of 1000 cases) was
recorded when test sensitivity is set to 1.0 and 270 when set to 0.1.
Figure 14 shows a comparison of the effects of varying different
parameters on drop-out rate. Considering mean drop-out rate is
224 with standard parameter settings, this chart indicates that only
Figure 8. Distribution of delays since onset of symptoms to
start of treatment for patients that do not drop out, with a 0.05
(top) and 0.10 (bottom) probability that patient makes a clinic
visit on a given day.
doi:10.1371/journal.pone.0001933.g008
Figure 9. The effect of changing the probabilities of a patient making visit ‘1’ and ‘V’ on mean delay.
doi:10.1371/journal.pone.0001933.g009
Figure 10. Distribution of delays since onset of symptoms to
start of treatment for patients that do not drop out, with a 0.95
(above) and 0.10 (below) probability that sputum is requested
on visit ‘V’.
doi:10.1371/journal.pone.0001933.g010
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by increasing initial SSM test sensitivity can sizeable reductions in
the mean drop-out rate be achieved. Theoretically, if sensitivity
was increased to 0.8, mean drop-out rate would be reduced to 202
and to 182 if sensitivity could be increased to 1.0.
Considering these parameter changes in isolation gives some
insight into their individual effect on delay and drop-outs. A
comparison of costs incurred by the healthcare system is also
included. Table 3 shows a comparison of the potential benefits of
such changes, relating them to different diagnostic scenarios.
The diagnostic approach used by the South African NTCP,
which is based on using two smears in the initial SSM test,
provides a benchmark in performance.
The following scenarios, listed in order of delay times from
shortest to longest, were compared:
N A theoretical scenario using a test that achieves around 60%
sensitivity and which can be processed in a single day while the
patient waits.
N The proportion of ss-patients treated presumptively based on
abnormal CXR results, increased from 0.1 to 0.5.
N The probability of making the first clinic visit, doubled to 0.1
on a given day.
N A so-called one-stop diagnosis using a test with 60% sensitivity.
N Diagnosis based on the use of two sputum smears.
N Diagnosis based on the use of three sputum smears.
N An HIV+ cohort of patients diagnosed by examination of two
sputum smears. (Model parameters were altered, specifically
sensitivity of the SSM test is lower and culture time is longer).
N Initial SSM is replaced by LJ culture.
A macro was used to increase each input parameter sequentially
by 20% in order to determine the sensitivity of the model to each
parameter (Table 4). From this analysis it is evident that increasing
the sensitivity of the initial diagnostic test has a relatively large
effect on mean delay, mean cost per patient and mean drop-out
rate. Mean delay and cost per patient is decreased the most by this
parameter change, causing around an 8% and 14% decrease
respectively.
Conclusion
This modelling investigation highlights the numerous patient and
healthcare system-related factors that contribute to the excessive
total delay currently experienced by TB patients in many developing
countries, before diagnosis and treatment is achieved. Such lengthy
delays are, in-part, accountable for the inability to control the
epidemic, as they allow time for a greater number of transmission
events and subsequently for the disease to spread.[9]
The most important of the delay factors is the sensitivity of the
initial SSM test. In developing countries, SSM is currently the
most effective tool for diagnosing pulmonary TB, as it is rapid,
cheap and has a high specificity; however it suffers from low
sensitivity.[10] Often in practice, the sensitivity of Ziehl-Neelsen
(ZN) smear is less than 50% when compared to culture.[11] TB
patients that are not identified by this initial test incur relatively
long delays as they must make additional hospital/clinic visits and
Figure 11. Relationship between the probability of sputum
being requested on visit ‘V’ and mean delay.
doi:10.1371/journal.pone.0001933.g011
Figure 12. The effect of ss-CXR and SSM sensitivity on mean
delay.
doi:10.1371/journal.pone.0001933.g012
Figure 13. Linear relationship between initial SSM test
sensitivity and percentage of patients that drop out.
doi:10.1371/journal.pone.0001933.g013
Figure 14. The effect of parameter changes on mean drop-out
rate.
doi:10.1371/journal.pone.0001933.g014
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undergo further testing. This study suggests that for every 0.1
increase in test sensitivity, a 3–5 day reduction in diagnostic delay
is possible. Therefore in order to significantly reduce the mean
total delay experienced by patients, the effectiveness of the initial
test is crucial.
Our analysis draw attention to the excessive delays associated
with smear negative TB patients, a finding that is supported in the
literature.[12] This patient group experiences particularly long
delays since they predominantly rely on sputum culture in order to
obtain a decisive diagnosis. The conventional culture method
using Lowenstein-Jensen (LJ) medium remains the so-called gold
standard, and is still widely used, both for diagnosis of smear
negative cases and drug sensitivity testing; however it requires up
to 8 weeks to complete.[8,13] Smear negative individuals are
typically less infectious when compared to smear positive patients
(approximately 20% relative infectiousness)[14] However due to
the low sensitivity of SSM, the number of patients missed by the
test makes up approximately half of all pulmonary TB cases and
thus represent a significant proportion (,10%, as calculated from
the above fractions) of potential transmission events. The
importance of introducing an appropriate new test for diagnosing
smear negative cases in a timelier manner should therefore be
emphasised.
The results from this investigation reinforce the importance that
patients should promptly seek the appropriate medical attention
following onset of TB symptoms. Mean delay is reduced by
7.3 days when the probability of a patient making the first visit to a
clinic on a given day is doubled from 0.05 to 0.1. In order for this
goal to be realised, the many obstacles that isolate different
population groups from the appropriate care need to be
overcome.[4,15] Case finding is identified in the model as being
a crucial factor with regards to diagnostic delay. Currently, a
passive approach is used in many developing countries, however it
may be necessary to adopt a more active approach if control of the
epidemic is to be realised.
The probability that a sputum sample is requested emerged as
an important issue, not surprisingly. For the standard scenario, the
input value for this probability was high (0.95) and therefore
increases in this parameter produce limited reductions in delay.
Table 3. A comparison of different theoretical diagnostic
scenarios.
Diagnostic method
Mean
Delay
Mean
Cost
Mean Drop-
out Rate
2 smears (Standard method)1 46.1 25.54 224.8
Same-day Diagnosis2 38.6 221.3
2 smears, treat ss-based on CXR3 38.7 21.50 218.7
2 smears, increase P(make visit)4 38.8 25.71 156.6
1-stop diagnosis5 43.4 219.8
2 smears6 43.8 24.10 219.6
3 smears7 45.2 28.00 219.6
2 smears HIV+patient cohort8 61.4 32.44 243.2
LJ culture9 66.3 183.2
Notes:
1.Sensitivity = 0.55, 2 days delay in producing SSM test results.
2.Sensitivity = 0.59 (same as for 3 smears), zero delay in delivering sputum,
producing results and in patient collecting results.
3.Sensitivity = 0.55, 2 days delay in producing SSM test results, P(treating ss-
based on CXR) = 0.5 (up from 0.1).
4.Sensitivity = 0.55, 2 days delay in producing SSM test results, P(make 1st visit to
clinic on given day) = 0.1 (up from 0.05).
5.Sensitivity = 0.59 (same as for 3 smears), zero delay in delivering sputum.
6.Sensitivity = 0.59 (same as for 3 smears due to reduced work load), 2 days
delay in producing SSM test results.
7.Sensitivity = 0.59, 3 days delay in producing SSM test results.
8.Sensitivity = 0.36, rates of abnormal CXR kept the same, culture time for ss-
patients = 8 weeks (up from 6), sensitivity ss-SSM kept the same.
9.LJ culture used in place of initial SSM test, culture time = 42 days,
sensitivity = 1.0
doi:10.1371/journal.pone.0001933.t003
Table 4. Percentage Change in Mean Delay Due to a 20%
Increase in Individual Parameters.
Parameters
Input
Values
Average Mean
Delay
% Change in Average
Mean Delay
PPV 0.55 42.1 28.07
NCHP 0.5 47.2 3.26
DNCHP 10 46.7 1.99
PHC1 0.05 43.8 24.35
PHC2 0.05 46.0 0.50
PHC3 0.05 46.1 0.76
PD10 0.01 47.3 3.33
PD20 0.01 46.1 0.85
PD30 0.01 45.6 20.32
PD11 0.01 45.8 0.06
PD21 0.01 46.4 1.46
PD31 0.01 46.7 2.04
PCXR1 0.10 47.0 2.84
PCXR2 0.10 46.1 0.79
PCXR3 0.10 45.8 0.01
SENCXR1 0.50 45.4 20.69
SENCXR2 0.50 46.4 1.34
SENCXR3 0.50 46.7 2.14
DELCXR 5 47.2 3.13
PS1 0.95 * 45.2 21.12
PS2 0.95 * 45.7 20.18
PS3 0.95 * 44.9 21.83
PD12 0.01 46.4 1.50
PD22 0.01 46.7 2.04
PD32 0.01 47.2 3.19
PD13 0.01 46.1 0.84
PD23 0.01 45.8 0.03
PD33 0.01 45.8 0.16
DEL11 1 46.3 1.22
DEL21 1 46.7 2.00
DEL31 1 47.2 3.26
DEL12 2 46.2 0.90
DEL22 2 45.7 20.03
DEL32 2 45.9 0.32
DEL13 2 46.3 1.15
DEL23 2 46.7 1.99
DEL33 2 47.2 3.13
DELTR 2 46.3 1.30
Note: The average mean delay corresponding to a 20% increase in the
particular parameter is compared to the standard mean delay of 45.7
doi:10.1371/journal.pone.0001933.t004
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However it is crucial that sputum is requested whenever there are
indications of TB. Therefore healthcare workers need to be alert to
the signs of TB particularly in lower risk groups such as children.
Simulations of two versus three smears used in the initial SSM
test are compared in this study. It is clear that overall test
sensitivity achieved by each approach is the crucial factor. While
disparity between the use of two and three smears with respect to
mean delay is small, the potential implications for the healthcare
system are significant. Overburdening of healthcare systems has a
particularly detrimental effect on TB diagnosis and where this is
the case it has been suggested that the two smear approach should
be considered.[16,17]
The importance of factors that influence patient drop-out rates
is also stressed; as such individuals will remain untreated and
infectious in the community, resulting in potential TB transmission
to their close contacts, including those caring for the sick person at
the later stages of the disease.
With the ever increasing threat of MDR and XDR-TB as well
as HIV, the goal posts for diagnosis have been moved. Continued
development of diagnostic strategies is needed in order to maintain
relevance. TB control is complex and it is clear that not all the
criteria for case detection will be met by a single diagnostic
method. How different methods are used concurrently is crucial to
the success of control programs.
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